Published in Haematologica on January 26, 2008
Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood (2008) 2.43
Circulating DNA and myeloperoxidase indicate disease activity in patients with thrombotic microangiopathies. Blood (2012) 1.87
Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura. Blood (2012) 1.73
Thrombotic microangiopathy and associated renal disorders. Nephrol Dial Transplant (2012) 1.44
An autoantibody epitope comprising residues R660, Y661, and Y665 in the ADAMTS13 spacer domain identifies a binding site for the A2 domain of VWF. Blood (2009) 1.27
Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura. Haematologica (2010) 1.27
Thrombotic microangiopathies. ISRN Hematol (2012) 0.99
The first deletion mutation in the TSP1-6 repeat domain of ADAMTS13 in a family with inherited thrombotic thrombocytopenic purpura. Haematologica (2008) 0.91
Human neutrophil peptides inhibit cleavage of von Willebrand factor by ADAMTS13: a potential link of inflammation to TTP. Blood (2016) 0.88
Advantages and limits of ADAMTS13 testing in thrombotic thrombocytopenic purpura. Blood Transfus (2008) 0.86
ADAMTS13 deficiency and thrombotic thrombocytopenic purpura associated with trimethoprim-sulfamethoxazole. Clin Med Res (2012) 0.84
An optimized fluorogenic ADAMTS13 assay with increased sensitivity for the investigation of patients with thrombotic thrombocytopenic purpura. J Thromb Haemost (2013) 0.84
Detection of autoantibodies in a point-of-care rheumatology setting. Auto Immun Highlights (2013) 0.82
Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS): a 24-year clinical experience with 178 patients. J Hematol Oncol (2008) 0.81
Attending rounds: microangiopathic hemolytic anemia with renal insufficiency. Clin J Am Soc Nephrol (2011) 0.81
Molecular basis of ADAMTS13 dysfunction in thrombotic thrombocytopenic purpura. Pediatr Nephrol (2008) 0.79
Novel recombinant glycosylphosphatidylinositol (GPI)-anchored ADAMTS13 and variants for assessment of anti-ADAMTS13 autoantibodies in patients with thrombotic thrombocytopenic purpura. Thromb Haemost (2011) 0.79
Pathogenesis and treatment of acquired idiopathic thrombotic thrombocytopenic purpura. Haematologica (2010) 0.78
Efficacy and Safety of Rituximab for Refractory and Relapsing Thrombotic Thrombocytopenic Purpura: A Cohort of 10 Cases. Clin Med Insights Blood Disord (2015) 0.77
Pathogenicity of Anti-ADAMTS13 Autoantibodies in Acquired Thrombotic Thrombocytopenic Purpura. EBioMedicine (2015) 0.76
ADAMTS13 autoantibodies cloned from patients with acquired thrombotic thrombocytopenic purpura: 1. Structural and functional characterization in vitro. Transfusion (2016) 0.76
ADAMTS-13 in the Diagnosis and Management of Thrombotic Microangiopathies. Rambam Maimonides Med J (2014) 0.76
ADAMTS13 autoantibodies cloned from patients with acquired thrombotic thrombocytopenic purpura: 2. Pathogenicity in an animal model. Transfusion (2016) 0.76
Unfavorable course in pregnancy-associated thrombotic thrombocytopenic purpura necessitating a perimortem Cesarean section: a case report. J Med Case Rep (2013) 0.76
A novel CD46 mutation in a patient with microangiopathy clinically resembling thrombotic thrombocytopenic purpura and normal ADAMTS13 activity. Haematologica (2014) 0.76
Identification of novel host biomarkers in plasma as candidates for the immunodiagnosis of tuberculosis disease and monitoring of tuberculosis treatment response. Oncotarget (2016) 0.75
Pregnancy complications in acquired thrombotic thrombocytopenic purpura: a case-control study. Orphanet J Rare Dis (2014) 0.75
Clinical importance of ADAMTS13 activity during remission in patients with acquired thrombotic thrombocytopenic purpura. Blood (2016) 0.75
Two novel heterozygote missense mutations of the ADAMTS13 gene in a child with recurrent thrombotic thrombocytopenic purpura. Blood Transfus (2012) 0.75
Pathophysiology of thrombotic thrombocytopenic purpura. Blood (2017) 0.75
The coagulopathy of chronic liver disease. N Engl J Med (2011) 5.63
Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med (2011) 4.37
Exposure to particulate air pollution and risk of deep vein thrombosis. Arch Intern Med (2008) 3.96
Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology (2006) 2.72
Prophylaxis of venous thromboembolism in elderly patients with multimorbidity. Intern Emerg Med (2013) 2.64
Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood (2012) 2.58
Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood (2007) 2.53
Embryo implantation after assisted reproductive procedures and maternal thrombophilia. Haematologica (2003) 2.38
Decreased ADAMTS-13 (A disintegrin-like and metalloprotease with thrombospondin type 1 repeats) is associated with a poor prognosis in sepsis-induced organ failure. Crit Care Med (2007) 2.37
The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. Blood (2007) 2.31
Plasmin cleavage of von Willebrand factor as an emergency bypass for ADAMTS13 deficiency in thrombotic microangiopathy. Circulation (2014) 2.16
Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood (2011) 2.04
Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL). Blood (2013) 2.03
Living near major traffic roads and risk of deep vein thrombosis. Circulation (2009) 1.98
ZAP-70 enhances B-cell-receptor signaling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B cells. Blood (2006) 1.95
Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells. Blood (2005) 1.88
The international normalized ratio calibrated for cirrhosis (INR(liver)) normalizes prothrombin time results for model for end-stage liver disease calculation. Hepatology (2007) 1.86
von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Blood (2002) 1.85
Thrombotic thrombocytopenic purpura directly linked with ADAMTS13 inhibition in the baboon (Papio ursinus). Blood (2010) 1.75
Risk of venous thromboembolism after air travel: interaction with thrombophilia and oral contraceptives. Arch Intern Med (2003) 1.75
Binding of von Willebrand factor to collagen and glycoprotein Ibalpha, but not to glycoprotein IIb/IIIa, contributes to ischemic stroke in mice--brief report. Arterioscler Thromb Vasc Biol (2010) 1.74
Risk factors and recurrence rate of primary deep vein thrombosis of the upper extremities. Circulation (2004) 1.73
Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura. Blood (2004) 1.67
Abnormalities of hemostasis in chronic liver disease: reappraisal of their clinical significance and need for clinical and laboratory research. J Hepatol (2007) 1.67
NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL. Haematologica (2011) 1.67
Deficiency of von Willebrand factor protects mice from ischemic stroke. Blood (2009) 1.65
Venous and arterial thrombosis: different sides of the same coin? Eur J Intern Med (2008) 1.65
Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study. Br J Haematol (2005) 1.63
Home hospitalization service for acute uncomplicated first ischemic stroke in elderly patients: a randomized trial. J Am Geriatr Soc (2004) 1.63
Expression of mutated IGHV3-23 genes in chronic lymphocytic leukemia identifies a disease subset with peculiar clinical and biological features. Clin Cancer Res (2010) 1.62
Inherited thrombophilia and first venous thromboembolism during pregnancy and puerperium. Thromb Haemost (2002) 1.62
Overexpression of the autoimmunity-associated phosphatase PTPN22 promotes survival of antigen-stimulated CLL cells by selectively activating AKT. Blood (2012) 1.61
Thrombosis in inflammatory bowel diseases: role of inherited thrombophilia. Am J Gastroenterol (2005) 1.61
New antiplatelet agents: why they are needed. Eur J Intern Med (2009) 1.58
Heparin in pregnant women with previous placenta-mediated pregnancy complications: a prospective, randomized, multicenter, controlled clinical trial. Blood (2012) 1.58
The Syk kinase as a therapeutic target in leukemia and lymphoma. Expert Opin Investig Drugs (2011) 1.58
Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood (2003) 1.57
Von Willebrand's disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment. Haematologica (2003) 1.56
How I treat rare venous thromboses. Blood (2008) 1.56
Immunophenotypic characterization of IgVH3-72 B-cell chronic lymphocytic leukaemia (B-CLL). Leuk Res (2006) 1.55
An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis. Gastroenterology (2009) 1.54
Abnormalities of hemostasis and bleeding in chronic liver disease: the paradigm is challenged. Intern Emerg Med (2009) 1.53
A new era for anticoagulants. Eur J Intern Med (2009) 1.53
Air pollution, smoking, and plasma homocysteine. Environ Health Perspect (2006) 1.53
The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. Blood (2011) 1.51
MGA, a suppressor of MYC, is recurrently inactivated in high risk chronic lymphocytic leukemia. Leuk Lymphoma (2012) 1.51
Polypharmacy, length of hospital stay, and in-hospital mortality among elderly patients in internal medicine wards. The REPOSI study. Eur J Clin Pharmacol (2011) 1.50
Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood (2009) 1.50
The risk of recurrent venous thromboembolism in pregnancy and puerperium without antithrombotic prophylaxis. Br J Haematol (2006) 1.47
Multi centric origin of Hb D-Punjab [beta121(GH4)Glu-->Gln, GAA>CAA]. Hemoglobin (2009) 1.45
Prognostic value of estimated glomerular filtration rate in hospitalized elderly patients. Intern Emerg Med (2013) 1.44
A G to C transversion at the last nucleotide of exon 25 of the MYH9 gene results in a missense mutation rather than in a splicing defect. Eur J Med Genet (2010) 1.41
Screening for HLA antibodies in plateletpheresis donors with a history of transfusion or pregnancy. Transfusion (2014) 1.41
Simultaneous genotyping of coagulation factor XI type II and type III mutations by multiplex real-time polymerase chain reaction to determine their prevalence in healthy and factor XI-deficient Italians. Haematologica (2008) 1.41
Internal and geriatric medicine: an alliance for the challenges of the elderly. Eur J Intern Med (2012) 1.40
CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy. Clin Pharmacol Ther (2004) 1.40
Pregnancy outcomes in asthmatic women. Iran J Allergy Asthma Immunol (2008) 1.39
Clinical and laboratory patterns of the haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura in southern Iran. Intern Emerg Med (2006) 1.39
The hemostatic balance revisited through the lessons of mankind evolution. Intern Emerg Med (2008) 1.39
ADAMTS13 content in plasma-derived factor VIII/von Willebrand factor concentrates. Am J Hematol (2013) 1.39
Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia. Blood (2013) 1.39
Global coagulation in myeloproliferative neoplasms. Ann Hematol (2013) 1.38
Frequency of combined factor V and factor VIII deficiency in southern Iran. Blood Coagul Fibrinolysis (2013) 1.38
The stigma of low opioid prescription in the hospitalized multimorbid elderly in Italy. Intern Emerg Med (2014) 1.38
Nitric oxide levels increase during platelet concentrate production from buffy coats, but not during storage. Transfusion (2013) 1.38
Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance. J Transl Med (2009) 1.35
Thrombospondin-1 controls vascular platelet recruitment and thrombus adherence in mice by protecting (sub)endothelial VWF from cleavage by ADAMTS13. Blood (2005) 1.35
Platelets at work in primary hemostasis. Blood Rev (2011) 1.34
Shielding of the A1 domain by the D'D3 domains of von Willebrand factor modulates its interaction with platelet glycoprotein Ib-IX-V. J Biol Chem (2005) 1.34
Position of nonmuscle myosin heavy chain IIA (NMMHC-IIA) mutations predicts the natural history of MYH9-related disease. Hum Mutat (2008) 1.34
von Willebrand factor cleaving protease (ADAMTS-13) and ADAMTS-13 neutralizing autoantibodies in 100 patients with thrombotic thrombocytopenic purpura. Br J Haematol (2004) 1.31
Predictive factors of in-hospital mortality in older patients admitted to a medical intensive care unit. J Am Geriatr Soc (2003) 1.29
ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood (2005) 1.27
ADAMTS13 mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura. Hum Mutat (2010) 1.26
Hyperhomocysteinemia in cerebral vein thrombosis. Blood (2003) 1.24
The thrombogram in rare inherited coagulation disorders: its relation to clinical bleeding. Thromb Haemost (2002) 1.23
The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood (2002) 1.23
Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome. Clin Cancer Res (2009) 1.22
The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia. Haematologica (2013) 1.21
Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease. Leuk Res (2010) 1.21
Von Willebrand factor cleaving protease (ADAMTS-13) in 123 patients with connective tissue diseases (systemic lupus erythematosus and systemic sclerosis). Haematologica (2003) 1.20
Age-related complications in treatment-naïve patients with thalassaemia intermedia. Br J Haematol (2010) 1.18
Factors associated with mortality in bacteremic patients with hematologic malignancies. Diagn Microbiol Infect Dis (2009) 1.17
Risk factors for thrombophilia in extrahepatic portal vein obstruction. Hepatology (2005) 1.17
Growth and endocrine disorders in thalassemia: The international network on endocrine complications in thalassemia (I-CET) position statement and guidelines. Indian J Endocrinol Metab (2013) 1.16